Hudson Bay Capital Management LP Takes Position in Sanofi $SNY

Hudson Bay Capital Management LP acquired a new stake in Sanofi (NASDAQ:SNY) during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 132,260 shares of the company’s stock, valued at approximately $6,243,000.

Several other hedge funds also recently added to or reduced their stakes in the business. Mondrian Investment Partners LTD purchased a new stake in Sanofi in the third quarter valued at $171,742,000. Raymond James Financial Inc. grew its holdings in shares of Sanofi by 81.3% during the 2nd quarter. Raymond James Financial Inc. now owns 5,879,894 shares of the company’s stock worth $284,058,000 after purchasing an additional 2,635,867 shares during the period. Thrivent Financial for Lutherans increased its position in shares of Sanofi by 10,152.1% during the 3rd quarter. Thrivent Financial for Lutherans now owns 2,200,107 shares of the company’s stock worth $103,846,000 after purchasing an additional 2,178,647 shares during the last quarter. BNP Paribas Financial Markets increased its position in shares of Sanofi by 422.1% during the 3rd quarter. BNP Paribas Financial Markets now owns 1,062,809 shares of the company’s stock worth $50,165,000 after purchasing an additional 859,246 shares during the last quarter. Finally, Victory Capital Management Inc. raised its holdings in Sanofi by 133.3% in the 3rd quarter. Victory Capital Management Inc. now owns 1,413,640 shares of the company’s stock valued at $66,681,000 after buying an additional 807,767 shares during the period. 14.03% of the stock is currently owned by hedge funds and other institutional investors.

Sanofi Price Performance

Shares of NASDAQ SNY opened at $44.60 on Friday. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.09 and a quick ratio of 0.73. The company has a market cap of $108.78 billion, a price-to-earnings ratio of 12.39, a price-to-earnings-growth ratio of 1.17 and a beta of 0.45. The stock’s 50-day moving average is $46.46 and its two-hundred day moving average is $48.05. Sanofi has a 1-year low of $43.32 and a 1-year high of $57.60.

Analysts Set New Price Targets

A number of research analysts have commented on the stock. Citigroup began coverage on shares of Sanofi in a research report on Tuesday, January 27th. They issued a “neutral” rating on the stock. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of Sanofi in a research note on Friday, January 16th. Wall Street Zen lowered shares of Sanofi from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 21st. TD Cowen reaffirmed a “hold” rating on shares of Sanofi in a research report on Tuesday, December 30th. Finally, Barclays downgraded shares of Sanofi from an “overweight” rating to an “equal weight” rating in a report on Tuesday, January 6th. Five investment analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $61.50.

Sanofi Company Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.